Verrica Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference

Rhea-AI Summary

Verrica Pharmaceuticals (Nasdaq: VRCA) announced that CEO Jayson Rieger will present at the TD Cowen 46th Annual Health Care Conference in Boston on March 2, 2026 at 10:30am ET.

According to the company, a live webcast will be available on Verrica's investor website and a replay will be posted and available for 90 days.

Key Figures

Conference date: March 2, 2026 Webcast replay period: 90 days Phase 2 clearance rate: 51% (18 of 35) +5 more

8 metrics

Conference date March 2, 2026 TD Cowen 46th Annual Health Care Conference presentation

Webcast replay period 90 days Replay availability following the TD Cowen presentation

Phase 2 clearance rate 51% (18 of 35) COVE-1 Cohort 2 complete clearance at Day 84 for YCANTH

Q3 2025 revenue $14.3M Third quarter 2025 financial results

Private placement size $50 million November 2025 PIPE financing to retire debt and fund operations

Q3 2025 net loss $0.3M Third quarter 2025 results

Current share price $5.79 Prior to TD Cowen conference participation announcement

Shelf shares registered 14,756,230 shares S-3 shelf registration for resale by existing stockholders

Market Reality Check

Price: $5.79 Vol: Volume 71,436 is light at...

low vol

$5.79 Last Close

Volume Volume 71,436 is light at 0.52x the 20-day average of 137,553 ahead of the conference news. low

Technical Shares at $5.79 are trading below the $6.01 200-day moving average after a -8.1% move.

Peers on Argus

VRCA’s -8.1% decline contrasts with mixed peers: PSTV -6.94%, OTLK -5.47%, CALC ...

1 Up

VRCA’s -8.1% decline contrasts with mixed peers: PSTV -6.94%, OTLK -5.47%, CALC -1.69%, RADX -0.6%, while GRCE is up 0.52%. Momentum scans only flag OTLK moving up, supporting a stock-specific move rather than a coordinated sector rotation.

Historical Context

5 past events · Latest: Feb 12 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 12	Executive appointment	Positive	-2.3%	Appointed veteran commercial leader as Chief Commercial Officer for YCANTH growth.
Feb 09	Product launch Japan	Positive	+0.0%	YCANTH launch in Japan by Torii after MHLW approval and positive Phase 3 data.
Jan 07	Clinical trial update	Positive	+0.9%	First patient dosed in global Phase 3 for common warts following strong Phase 2.
Nov 24	Private placement financing	Positive	+12.1%	Raised about $50M via PIPE to retire debt and extend cash runway into 2027.
Nov 14	Earnings update	Neutral	-5.1%	Reported Q3 2025 revenue, YCANTH growth and regulatory feedback alongside small net loss.

Pattern Detected

Recent history shows several instances where positive operational or strategic news was followed by flat or negative price moves, with stronger alignment mainly around financing and key clinical milestones.

Recent Company History

Over the last few months, Verrica reported multiple developments: a new Chief Commercial Officer on Feb 12, 2026 with over 25 years’ experience, a Japan launch of YCANTH on Feb 9, 2026, and first dosing in a global Phase 3 program announced on Jan 7, 2026. In late 2025, the company raised about $50 million via private placement to retire OrbiMed debt and extend cash runway, and reported Q3 2025 revenue of $14.3M. Today’s conference participation fits into this ongoing execution and communication cadence.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2025-12-15

An effective S-3 shelf dated Dec 15, 2025 registers up to 14,756,230 common shares for resale by existing stockholders, including shares underlying pre-funded and common warrants. Verrica would receive cash only upon warrant exercises at $0.0001 and $6.315 per share; auditors have previously expressed substantial doubt about its ability to continue as a going concern.

Market Pulse Summary

This announcement adds an investor-relations touchpoint as Verrica’s CEO presents at TD Cowen’s conf...

Analysis

This announcement adds an investor-relations touchpoint as Verrica’s CEO presents at TD Cowen’s conference on March 2, 2026, with a webcast and 90‑day replay. It follows recent milestones including the Japan launch of YCANTH, initiation of a global Phase 3 program, and a $50 million financing that retired debt and extended runway. Investors may watch for any incremental disclosures at the conference against the backdrop of an outstanding S-3 resale shelf and prior going‑concern commentary.

Key Terms

shelf registration statement, pre-funded warrants, series c warrant, series b warrants, +4 more

8 terms

shelf registration statement regulatory

"is registering up to 14,756,230 shares of common stock for resale by existing stockholders under a shelf registration statement."

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

pre-funded warrants financial

"up to 5,305,164 shares issuable upon exercise of pre-funded warrants, and up to 2,951,240 shares issuable upon exercise of common warrants"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

series c warrant financial

"Each unit also included a Series C warrant, giving the right to buy one fourth of a share"

A Series C warrant is a contract issued alongside a Series C financing round that gives the holder the right to buy company shares at a set price for a limited time. Think of it like a discounted ticket to buy stock later: it can offer extra upside if the company’s value rises, but it also represents potential future dilution for existing shareholders and can change the ownership mix and value per share.

series b warrants financial

"The filing lists Series B Warrants, immediately exercisable, for 224,719 shares of Verrica common stock"

Series B warrants are contracts issued alongside a company's Series B financing that give the holder the right to buy a set number of shares at a fixed price within a specified time. For investors, they matter because they can provide leveraged upside if the company grows, or they can dilute existing shareholders when exercised—like a coupon promising a future share at a known price that can add value or change ownership stakes.

reverse stock split financial

"did not reflect Verrica’s 1-for-10 reverse stock split that took effect on July 24, 2025."

A reverse stock split is when a company reduces the number of its shares outstanding, making each share more valuable. For example, if you own 100 shares worth $1 each, a 1-for-10 reverse split would turn your 100 shares into 10 shares worth $10 each. Companies often do this to boost their stock price and appear more stable to investors.

pipe financing financial

"announced a private placement PIPE financing raising approximately $50 million in gross proceeds"

Pipe financing is a way for companies to raise money quickly by selling new shares or bonds directly to investors, often before their stock is publicly traded or in the early stages of a project. It’s similar to a company securing a loan from investors, providing quick capital needed for growth or operations. For investors, it can offer opportunities for early involvement and potentially higher returns, but it may also carry increased risk due to the immediate nature of the deal.

phase 3 medical

"global Phase 3 program evaluating YCANTH (VP-102) for common warts."

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

molluscum contagiosum medical

"YCANTH for the treatment of molluscum contagiosum."

Molluscum contagiosum is a common viral skin infection that causes small, painless bumps or lesions on the skin. While it primarily affects children and healthy adults, it can spread easily through skin contact. For investors, understanding health conditions like this highlights the importance of healthcare companies involved in treatments and the potential impact of infectious diseases on public health and economic stability.

AI-generated analysis. Not financial advice.

WEST CHESTER, Pa., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the TD Cowen 46^th Annual Healthcare Conference in Boston.

TD Cowen 46^th Annual Health Care Conference, March 2-4, 2026
Event details:
Date: Monday, March 2, 2026
Time: 10:30am ET
Location: Boston, Massachusetts

Participants may access a live webcast of the event by clicking the link here.

The webcast can also be accessed in the Investors/Presentations & Events section of the Verrica website at www.verrica.com. A replay of the webcast will be posted shortly after the presentation and will be available for 90 days following the event.

About Verrica Pharmaceuticals Inc. 
Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica’s product YCANTH^® (VP-102) (cantharidin), is the first and only healthcare professional-administered treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH^® (VP-102) is also in development to treat common warts, the largest remaining unmet need in medical dermatology. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (ruxotemitide, formerly known as LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma.   For more information, visit www.verrica.com.

FOR MORE INFORMATION, PLEASE CONTACT:
Investors:

John J Kirby 
Interim Chief Financial Officer 
jkirby@verrica.com

Kevin Gardner 
LifeSci Advisors 
kgardner@lifesciadvisors.com

FAQ

When will Verrica (VRCA) present at the TD Cowen 46th Annual Health Care Conference?

Verrica will present on Monday, March 2, 2026 at 10:30am ET. According to the company, CEO Jayson Rieger will deliver the presentation in Boston during the conference running March 2-4, 2026.

How can investors watch Verrica's (VRCA) TD Cowen conference presentation on March 2, 2026?

Investors can access a live webcast via Verrica's investor site or the conference link. According to the company, the webcast is available on www.verrica.com under Investors/Presentations & Events.

Will Verrica (VRCA) provide a replay of the March 2, 2026 conference presentation?

Yes, a replay will be posted and available for 90 days after the presentation. According to the company, the replay will be accessible on the Verrica website shortly after the live webcast ends.

Who will present for Verrica (VRCA) at the TD Cowen healthcare conference on March 2, 2026?

Jayson Rieger, PhD, MBA, President and CEO, will present for Verrica. According to the company, he will represent Verrica and discuss company developments during the March 2, 2026 session.

Where is the TD Cowen 46th Annual Health Care Conference presentation by Verrica (VRCA) taking place?

The presentation will take place in Boston, Massachusetts as part of the TD Cowen conference. According to the company, Verrica's session is scheduled for March 2, 2026 at 10:30am ET.

How long will Verrica's (VRCA) conference replay remain available after the March 2, 2026 presentation?

The replay will remain available for 90 days following the presentation. According to the company, investors can view the replay on Verrica's investor website during that 90-day window.